Manuel Suarez, M.D. Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1435 W 49th Pl, Suite 207, Hialeah, FL 33012 Phone: 305-556-8556 Fax: 305-556-6112 |
Peter George Lindo, M.D. Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 W 68th St, Hialeah, FL 33016 Phone: 305-661-9404 Fax: 305-661-1510 |
Maria Elena Ocasio-tascon, MD Internal Medicine - Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2001 W 68th St, Hialeah, FL 33016 Phone: 305-661-9401 |
Raul Alejandro Fernandez, D.O. Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 2639 W 72nd St, Hialeah, FL 33016 Phone: 305-335-0041 |
Dr. Ernesto E Fonts, Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 777 E 25th St, Suite 512, Hialeah, FL 33013 Phone: 305-696-5007 Fax: 305-835-8907 |
Dr. Julio Chacon, M.D. Internal Medicine - Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 777 E 25th St, Hialeah, FL 33013 Phone: 305-251-3991 |
News Archive
Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.
How does the brain form "fear memory" that links a traumatic event to a particular situation? A pair of researchers at the University of California, Riverside, may have found an answer.
A diagnosis of idiopathic pulmonary fibrosis is not much better than a death sentence, given a survival rate averaging 4 to 6 years as the disease robs its victim of the ability to breathe.
Watson Pharmaceuticals, Inc. today confirmed that Actavis South Atlantic LLC, which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Oxymorphone Hydrochloride Extended-release Tablets.
› Verified 5 days ago